BioLineRx (BLRX) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioLineRx (BLRX) has outperformed Medicus Pharma (MDCX) over the past year, losing 49.8% versus a loss of 95.9%. BioLineRx is the larger company by market cap ($11.0 million vs $7.3 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | MDCX |
|---|---|---|
| Share price | $2.21 | $0.1019 |
| Market cap | $11.00M | $7.31M |
| 1-day change | +0.23% | -36.39% |
| YTD return | -20.22% | -93.34% |
| 1-year return | -49.77% | -95.86% |
| 5-year return | -98.19% | — |
| EPS (TTM) | $0.00 | $-2.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.50 | $2.78 |
| 52-week low | $2.15 | $0.0941 |
| Distance from 52-week high | -50.89% | -96.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +895.48% | +4316.09% |
| Average volume | 16.27K | 4.43M |
| Shares outstanding | 4.98M | 71.71M |
| Employees | 20 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLRX has outperformed MDCX by 46.1 percentage points over the past year.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Healthcare · Biotechnology · 20 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Healthcare · Drug Manufacturers - General · 16 employees
BLRX vs MDCX FAQ
Which is bigger, BioLineRx or Medicus Pharma?
BioLineRx (BLRX) is larger, with a market capitalization of $11.00M compared with $7.31M for Medicus Pharma (MDCX).
Which stock has performed better over the past year, BLRX or MDCX?
BLRX returned -49.77% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and Medicus Pharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for BioLineRx and Drug Manufacturers - General for Medicus Pharma.